Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?-Reference-Cited by-同舟云学术

Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?

Published:2017 Issue: Volume:2017 Page:1-6
ISSN:2090-3170
Container-title:International Journal of Breast Cancer
language:en
Short-container-title:International Journal of Breast Cancer

Author:

Cazzaniga M. E.¹²^ORCID,Cortesi L.³,Ferzi A.⁴,Scaltriti L.⁵,Cicchiello F.²,Ciccarese M.⁶,Torre S. Della⁷,Villa F.⁸,Giordano M.⁹,Verusio C.¹⁰,Nicolini M.¹¹,Gambaro A. R.¹²,Zanlorenzi L.¹³,Biraghi E.¹⁴,Casini E.²,Legramandi L.¹⁵,Rulli E.¹⁵^ORCID

Affiliation:

1. Research Unit Phase I Trials, ASST Monza, Monza, Italy

2. Oncology Unit, ASST Monza, Monza, Italy

3. Haematology and Oncology Unit, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy

4. Oncology Unit, ASST Ovest Milanese, Legnano, Italy

5. Oncology Day Hospital Unit, Ospedale Civile di Guastalla, Guastalla, Italy

6. Oncology Unit, Ospedale Vito Fazzi, Lecce, Italy

7. Oncology Unit, ASST Rhodense-Presidio di Garbagnate Milanese e Presidio di Rho, Garbagnate, Italy

8. Oncology Unit, ASST Lecco, Lecco, Italy

9. Oncology Unit, ASST Lariana, Como, Italy

10. Oncology Unit, ASST della Valle Olona, Saronno, Italy

11. Oncology Day Hospital Unit, Azienda USL Romagna, Cattolica, Italy

12. Oncology Unit, ASST Fatebenefratelli-Sacco, Milano, Italy

13. Oncology Unit, ASST della Valle Olona, Busto Arsizio, Italy

14. Oncology Unit, ASST Melegnano-Martesana, Gorgonzola, Italy

15. Methodology for Clinical Research Laboratory, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy

Abstract

Triple-negative breast cancer (TNBC) shows a very bad prognosis, even in early stages of disease. Metronomic chemotherapy refers to the minimum biologically effective dose of a chemotherapy agent given as a continuous dosing regimen with no prolonged drug-free breaks that leads to antitumor activity. In the present article, we review preclinical and clinical data of metronomic administration of chemotherapy agents with or without biological agents in TNBC cell lines and patients, contextually reporting data from the VICTOR-2 study in the subgroup of patients with TNBC, in order to stimulate new ideas for the design of clinical trials in this subset of patients.

Publisher

Hindawi Limited

Subject

Cancer Research,Pharmacology (medical),Oncology

Link

http://downloads.hindawi.com/journals/ijbc/2017/1683060.pdf

Reference18 articles.

1. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents

2. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype

3. Metronomic chemotherapy for triple negative breast cancer?

4. Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance

5. Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor–Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study;Breast Cancer Research and Treatment;2021-09-21

2. Metronomic Therapy in Oral Squamous Cell Carcinoma;Journal of Clinical Medicine;2021-06-26

3. Senescence-Induced Chemoresistance in Triple Negative Breast Cancer and Evolution-Based Treatment Strategies;Frontiers in Oncology;2021-06-24

4. Metronomic therapy in advanced breast cancer and NSCLC: vinorelbine as a paradigm of recent progress;Expert Review of Anticancer Therapy;2020-10-22

5. Recent clinical evidence on metronomic dosing in controlled clinical trials: a systematic literature review;Acta Oncologica;2020-04-10